Amgen GmbH

Industry / private company


Location: München, Germany (DE) DE

ISNI: 0000000405384576

ROR: https://ror.org/02ezy5072

Show on Map:

close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types (2020) Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, et al. Journal article, Review article Anti–B-cell maturation antigen bite molecule AMG 420 induces responses in multiple myeloma (2020) Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, Kroenke J, et al. Journal article A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells (2018) Brey CU, Proff J, Teufert N, Salzer B, Brozy J, Muenz M, Pendzialek J, et al. Journal article CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells (2018) Jitschin R, Saul D, Braun M, Tohumeken S, Kischel R, Lutteropp M, Dos Santos C, et al. Journal article Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study (2016) Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, Noppeney R, et al. Journal article